Clinical Trial: A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT06881251) titled 'A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)' on March 12.

Brief Summary: The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.

Study Start Date: Feb. 26

Study Type: INTERVENTIONAL

Condition: Dermatitis, Atopic

Intervention: DRUG: Dupilumab

Dupilumab will be administered subcutaneously.

DRUG: JNJ-95475939

JNJ-95475939 will be administered subcutaneously.

DRUG: Placebo

Placebo will be administered subcutaneously.

Recruitment Status: RECRUITING

Sponsor: Janssen Resear...